Genentech faces crucial Avastin decision

South San Francisco-based Genentech is nearing a crucial final decision from the FDA on the use of Avastin for breast cancer. An approval, notes the San Francisco Business Times, could boost its revenue by a billion dollars a year. If regulators agree with an advisory committee's recommendation against Avastin, though, the biotech giant stands to lose out big time in the breast cancer market. Genentech currently earns significant revenue from physicians' use of the drug as a therapy for breast cancer--money that is likely to evaporate rapidly with any rejection of its application.

- see this release
- read the story from the San Francisco Business Times

Related Articles:
Genentech's blistering growth starts to cool. Report
Will FDA care about new Avastin study? Report
EU blesses Avastin for broader use. Report
FDA: Avastin lackluster in breast cancer. Report
Avastin re-submitted to FDA. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.